Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
Intravenous delivery of adenovirus vectors requires that the virus is not inactivated in the bloodstream. Serum neutralizing activity is well documented, but we show here that type 5 adenovirus also interacts with human blood cells. Over 90% of a typical virus dose binds to human (but not murine) er...
Main Authors: | Lyons, M, Onion, D, Green, N, Aslan, K, Rajaratnam, R, Bazan-Peregrino, M, Phipps, S, Hale, S, Mautner, V, Seymour, L, Fisher, K |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2006
|
Similar Items
-
Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.
by: Carlisle, R, et al.
Published: (2006) -
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
by: Bazan-Peregrino, M, et al.
Published: (2008) -
Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition
by: Carlisle, R, et al.
Published: (2011) -
Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors.
by: Carlisle, R, et al.
Published: (2001) -
Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors
by: Carlisle, RC, et al.
Published: (2016)